Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458410 | 1.00 | CALCRL (0.61) | CALCRLCALCA | |
| SCHEMBL4457142 | 0.88 | CALCRL (0.64) | CALCRLCALCA | |
| SCHEMBL2025348 | 0.87 | CALCRL (0.59) | CALCRLCALCA | |
| SCHEMBL4308777 | 0.83 | CALCRL (0.63) | CALCRLCALCA | |
| SCHEMBL12050400 | 0.78 | CALCRL (0.75) | CALCRLCALCA | |
| SCHEMBL2026863 | 0.77 | CALCRL (0.61) | CALCRLCALCA | |
| SCHEMBL12580812 | 0.76 | CALCRL (1.00) | CALCRLCALCA | |
| SCHEMBL2020803 | 0.76 | CALCRL (1.00) | CALCRLCALCA | |
| SCHEMBL12580816 | 0.76 | CALCRL (1.00) | CALCRLCALCA | |
| SCHEMBL4313314 | 0.75 | CALCRL (0.64) | CALCRLCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951051-B1 | SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | CALCRL 4/4885CALCA 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.